Background: Previous studies convincingly showed an increase in risk of breast cancer
Substantial data demonstrate little, if any, association between use of oral contraceptives ten or more years in the past and risk of breast cancer (1-2). However, in earlier reports from the prospective Nurses' Health Study (3) and in a pooled analysis of 53,297 cases and 100,239 controls (4-5) mainly from case-control studies conducted in the 1970's and 1980's, a modest increase in risk was observed among women who were currently using oral contraceptives, or who had stopped using them in the preceding 10 years. However, few studies have examined the relation of newer formulations of oral contraceptives as used in the 1990's with breast cancer risk. A recent large case-control study (6) reported an odds ratio of 0.9 (95 percent confidence interval 0.8-1.0) for past use of more recent oral contraceptive preparations, and no elevation in risk for current use (odds ratio 1.0, 95 percent confidence interval 0.8 to 1.3). However, the upper bound of the confidence interval for current use included the odds ratio from the pooled analysis (odds ratio = 1.24 for current or recent use). A hospital-based case-control study conducted between 1993 and 2007 observed an increased odds ratio for one or more years of oral contraceptive use of 1.5 (95 percent confidence interval 1.2 to 1.8). although this reflected mainly use more than 5 years prior to diagnosis (7) .
To provide accurate estimates of any risks associated with more contemporary oral contraceptive formulations, we analyzed data from the Nurses' Health Study II, a study specifically designed to provide prospective data on the association of these oral contraceptives and breast cancer among mainly premenopausal women.
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Copyright © 2010 American Association for Cancer Research 5 separate codes for 21 versus 28 day pills with the same pharmacologic formulation and dose, and separate codes for different pharmacologic formulations and doses sold under the same brand name. For each year of age at which an oral contraceptive was used for >2 months, we asked women to indicate from the booklet which brand was used (and, if multiple brands were used at that age, the brand used the longest). This information was summarized into a time-dependent variable categorizing each woman as a never, past, or current user of any type of oral contraceptive.
On each subsequent biennial questionnaire, we asked each woman whether she was currently using oral contraceptives and for how many months she had used oral contraceptives in the previous two years (precoded response categories were 1 or less months, 2-4, 5-9, 10-14, 15-19, and 20 or more months). We asked each woman to indicate the brand and type of oral contraceptive used longest during this time period, and we provided a list of brands currently marketed as a memory aid.
To assess the reliability and accuracy of the baseline questionnaire assessment of oral contraceptive use, we conducted telephone interviews with a random sample of 215 participants an average of 11 months after they completed the baseline questionnaire (8) . In brief, women were sent a "life events calendar" to review during the interview. Using a structured protocol, the interviewers sought information about reproductive events, life milestones, and changes of address. Women were then asked to identify all periods of contraceptive use, around the framework of these other life events. From a subset of women, we obtained physician records of the contraceptive prescription corresponding to these intervals. Agreement between the two women who gave us permission to obtain oral contraceptive prescription records, the medical record confirmed the use of an identical or equivalent brand in 75% of intervals of reported use, and many of the disagreements were due to minor differences in dose.
IDENTIFICATION OF BREAST CANCER CASES
On each follow-up questionnaire, we asked participants whether they had been diagnosed with breast cancer in the previous two years. Deaths in the cohort are reported by family members and the postal service or are detected by an annual search of the National Death Index.
When a case of breast cancer was identified, we asked the participant (or next of kin for those who had died) for confirmation of the diagnosis and permission to seek relevant hospital records and pathology reports. For cases for whom we obtained a pathology report, the self-reported diagnosis of breast cancer was confirmed in 99 percent of the records. After exclusion of cases rejected on the basis of the pathology reports, cases with missing date of diagnosis and cases of carcinoma-in-situ, 1,388 cases of invasive breast cancer were available for analysis. We included 161 cases whose diagnosis was based on self-report only, because the accuracy of selfreport was so high. A further 44 cases were excluded because of missing information on current oral contraceptive use, leaving 1,344 cases in the analysis. for effect modification of the relation of current oral contraceptive use to breast cancer risk by performing analyses stratified by the above covariates, and by including appropriate interaction terms in the multivariate models. The population attributable risk percent was calculated using a standard formula (9) . We calculated incidence rates standardized to the age-distribution of women in the cohort. Statistical analysis was performed using SAS statistical software (SAS Institute Inc, Cary, NC).
STATISTICAL ANALYSIS

RESULTS
Baseline characteristics of oral contraceptive users are presented in Table 1 . Compared with never and past users, current oral contraceptive users were more likely to be nulliparous, to have no history or a limited duration of breastfeeding, to consume alcohol, and to be non-obese.
These variables, along with others, were controlled for in subsequent multivariate analyses.
The association of oral contraceptive use with breast cancer risk is presented in Table 2 . 
DISCUSSION
We found that current use of oral contraceptives was associated with breast cancer risk among women using the formulations commonly prescribed in the 1990's. Our findings also suggest that current use of triphasic preparations containing levonorgestrel as the progestin is associated with higher risk than use of other formulations. Although we found no overall increase in risk with past use of oral contraceptives, an increased risk due to long-term past use of triphasic EE/LNG preparations cannot be excluded and requires further evaluation. and norethindrone-containing formulations (odds ratio, 1.4; 95 percent confidence interval, 1.0-1.8) were marginally significantly associated with increased breast cancer risk. Odds ratios observed for the less commonly used preparations containing ethynodiol diacetate (odds ratio 1.9; 95 percent confidence interval, 0.9-4.2) and norethindrone acetate (odds ratio 1.9; 95 percent confidence interval, 0.9-3.8) were higher, but not statistically significant. In our study, a striking elevation in risk was present for triphasic levonorgestrel-containing preparations, and the two major brands with this formulation had equivalent relative risks. Neither monophasic preparations with levonorgestrel as the progestin, nor triphasic preparations with norethindrone as the progestin were associated with increased risk. This suggests that the dosage schedule associated with triphasic levonorgestrel use may confer risk, but that use of triphasic preparations with other progestins may not convey this risk. Interestingly, in a study of breast cancer survival among younger women, risk of death was increased if the most recent oral contraceptive used prior to diagnosis included levonorgestrel, but no association was seen for other progestin types (16) .
Concern regarding progestins in oral contraceptives has been strengthened by findings in postmenopausal women that the addition of progestin to estrogen greatly increases risk of breast cancer (17) (18) (19) . Breast cell proliferation assessed by thymidine labeling index is higher in the second half of the menstrual cycle, when progesterone levels are highest (20) (21) . Analyses of proliferation markers in fine needle aspirate biopsies from healthy women confirm a positive correlation of proliferation with serum progesterone levels on the day of aspiration (22) . Among 26 women who underwent fine needle aspirate biopsies before and after 2 months of oral contraceptive use, proliferation was increased during oral contraceptive use (23) . In a randomized trial of 42 women who received one cycle of an oral contraceptive containing 30ug ethinyl estradiol and 150ug levonorgestrel, breast tissue proliferative activity in the first week was increased compared with 40 women undergoing a normal menstrual cycle (24) . Among 37 women using oral contraceptives containing levonorgestrel, breast epithelial cell proliferation was significantly positively correlated (Spearman r = 0.43) with serum concentrations of levonorgestrel (23) . In animal assays of progestin activity, levonorgestrel is substantially more potent than the other commonly used progestins (25) ; however, the doses used in oral contraceptives are lower in an attempt to make the progestin action equipotent (26) .
Levonorgestrel is also the most androgenic of the currently used progestins (27) ; a positive relation between serum androgens and breast cancer risk was observed in a pooled analysis of data from nested case-control studies (28) . In addition to the type and dose of progestin, the Our study has several advantages compared with previous investigations of this issue. Its prospective design, with a high follow-up rate, limits the potential for recall bias or selection bias to influence the relative risks observed. In addition, we documented the validity of our assessment in this population of lifetime oral contraceptive use at baseline in 1989 (29).
Furthermore, it seems reasonable to expect that contemporary reporting of the current oral contraceptive brand during follow-up will be even more accurate than the report of past brand use at baseline, as assessed in our validation study.
We also had extensive, prospectively collected, information on other breast cancer risk factors that could confound the relation between oral contraceptive use and breast cancer.
Current oral contraceptive users had an increased prevalence of several breast cancer risk factors (nulliparity, limited breast feeding, alcohol consumption, and low BMI) that might modestly confound associations with current use. However, control of these and other factors in multivariate models resulted in very little change between the age-adjusted and multivariate point estimates, suggesting little potential for residual confounding by the covariates we measured.
The major limitation of our study is the relatively small number of cases that occurred among women currently using oral contraceptives because breast cancer incidence rates are low at the ages that most women typically use oral contraceptives. The attributable risk associated with 
